Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Concert licenses deuterated version of dextromethorphan to Avanir

Executive Summary

Drug discovery company Concert Pharmaceuticals Inc. has licensed Avanir Pharmaceuticals Inc. (CNS and viral diseases) exclusive worldwide rights to multiple versions of dextromethorphan analogs that incorporate deuterium (d-DM). The agreement includes Concert’s CTP786 (formerly C10003), in preclinical studies for pain and pseudobulbar affect (PBA; sudden outbursts of uncontrollable emotional displays).
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Technologies
      • Molecular Diversity
        • Natural Products
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • Intra-Biotech Deal
    • R&D and Marketing (Licensing)

Related Companies